Zobrazeno 1 - 4
of 4
pro vyhledávání: '"B L Hatcher"'
Autor:
Jeffrey A. Kirkwood, D L Hyslop, T E Mabry, B L Hatcher, G D Place, Joyce A. Compton, Ronald R. Bowsher, Karl A. DeSante, C D Jones
Fialuridine (FIAU) is a halogen-substituted analog of thymidine that was undergoing clinical investigation as a drug for the treatment of chronic hepatitis B viral infection. However, clinical trials of FIAU were terminated after adverse events occur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5583f9e39b839ea0125fe2f9c0bcd2ca
https://europepmc.org/articles/PMC284697/
https://europepmc.org/articles/PMC284697/
Autor:
P M, Franz, E L, Mattiuz, B L, Hatcher, K A, DeSante, A P, Breau, J L, Occolowitz, D E, Dorman, C R, Schmid, M J, Goldberg, A, Rubin
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 21(2)
Zatosetron is being tested clinically as an antianxiety agent; it is a highly selective antagonist of the serotonin 5-HT3 receptor, with minimal agonist activity. The disposition of [14C]zatosetron was studied in five healthy men after a single oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6f8aa3c2219252f63efbad4c31cfab1a
https://pubmed.ncbi.nlm.nih.gov/8097693
https://pubmed.ncbi.nlm.nih.gov/8097693
Publikováno v:
Postgraduate medical journal. 68
The pharmacokinetics and bioavailability of cefaclor advanced formulation (cefaclor AF) were investigated in two studies, one comparing healthy elderly and younger volunteers and the other assessing the effects of an antacid and H2-receptor antagonis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::637b87d75718e8fa8c295146344966e5
https://pubmed.ncbi.nlm.nih.gov/1287615
https://pubmed.ncbi.nlm.nih.gov/1287615
Publikováno v:
Antimicrobial Agents and Chemotherapy. 21:58-61
The effects of probenecid on the pharmacokinetics of moxalactam were studied in normal volunteers administered a 2-min l-g intravenous infusion. The results showed that probenecid did not alter the plasma or urinary concentrations of moxalactam, its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::124846130978f71be4085e05e381b4b9
https://doi.org/10.1128/aac.21.1.58
https://doi.org/10.1128/aac.21.1.58